OTCMCEOS
Market cap411kUSD
Dec 24, Last price
0.03USD
1D
-1.54%
1Q
77.78%
Jan 2017
216.83%
IPO
-89.33%
Name
CeCors Inc
Chart & Performance
P/E
—
P/S
0.98
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.62%
Rev. gr., 5y
206.78%
Revenues
419k
+2,070.73%
Net income
-1m
L+165.98%
CFO
160k
P
Earnings
Mar 31, 2025
Profile
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | |||||||||
Revenues | 419 2,070.73% | 19 | |||||||
Cost of revenue | 3 | ||||||||
Unusual Expense (Income) | |||||||||
NOPBT | 416 | 19 | |||||||
NOPBT Margin | 99.21% | 100.00% | |||||||
Operating Taxes | (1) | 2 | (237) | ||||||
Tax Rate | 9.38% | ||||||||
NOPAT | 417 | 18 | 237 | ||||||
Net income | (1,324) 165.98% | (498) 44.82% | (344) | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 386 | 697 | |||||||
Long-term debt | 625 | 625 | 510 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 635 | 1,319 | 439 | ||||||
| Cash flow | |||||||||
Cash from operating activities | 160 | (93) | (92) | ||||||
CAPEX | (160) | ||||||||
Cash from investing activities | 32 | 13 | |||||||
Cash from financing activities | 186 | 28 | 150 | ||||||
FCF | 1,445 | (341) | 584 | ||||||
| Balance | |||||||||
Cash | 376 | 3 | 71 | ||||||
Long term investments | |||||||||
Excess cash | 355 | 2 | 71 | ||||||
Stockholders' equity | (2,099) | (896) | (58) | ||||||
Invested Capital | 2,363 | 1,406 | 206 | ||||||
ROIC | 22.13% | 2.17% | 114.80% | ||||||
ROCE | 157.60% | 3.79% | |||||||
| EV | |||||||||
Common stock shares outstanding | 332,080 | 348,811 | 498,973 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | 418 | 19 | |||||||
EV/EBITDA | |||||||||
Interest | 28 | 140 | 12 | ||||||
Interest/NOPBT | 6.61% | 725.59% | |||||||